Buprenorphine Product Use

    Basic Details
    Date Posted
    Sunday, November 9, 2014
    Status
    Complete
    Medical Product
    buprenorphine
    Description

    Modular program-based one-time assessment use of Buprenorphine products both separately and as one drug category among all members (Overall) as well as those with a pre-existing diagnosis found in one of three composite categories: addiction-related diagnoses (16 codes), pain-related diagnoses (22 codes), and other defined diagnoses (8 codes). The query was run against the Mini-Sentinel Distributed Database (MSDD) for the time period of January 1, 2009 through December 31, 2010.  Modular programs are adaptable standardized programs. Results were generated using Modular Program 2, version 3.1; click here for more information.  Queries were distributed in February 15, 2010. This report includes data from 4 Data Partners.

    If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to info@mini-sentinel.org.

    The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

    Additional Details
    FDA Center
    CDER
    Time Period
    January 1, 2009 - December 31, 2010
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    All individuals with pre-existing codes in addiction or pain
    Data Sources
    Mini-Sentinel Distributed Database (MSDD)